Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Burke

Showing results (21-30 of 110) with videos related to

Pageof 11
Sort By:
Frontiers in Oncology|April 11, 2022
Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1Vamsidhar Velcheti, Xiaohan Hu, Lingfeng Yang, et al.
JAAD Case Reports|September 22, 2017
Remission of hidradenitis suppurativa after bariatric surgeryCatriona Gallagher, Shivashini Kirthi, Thomas Burke, et al.
Immunotherapy|June 12, 2019
First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatmentVamsidhar Velcheti, Sheenu Chandwani, Xin Chen, et al.
Clinical Therapeutics|October 9, 2007
Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational studyEric Van Ganse, Laurent Laforest, Thomas Burke, et al.
Lung Cancer (Amsterdam, Netherlands)|April 11, 2021
Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparisonBalazs Halmos, Thomas Burke, Chrysostomos Kalyvas, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|November 29, 2005
Does the crack silently break the back? Long-term follow-up and assessment of risk factors for regional osteoporosis following tibial shaft fracturesMohamed Khalid, Gregory Heffernan, Ann Brannigan, et al.
Frontline Gastroenterology|December 31, 2021
Recent advances in liver transplantationN Thomas Burke, James B Maurice, David Nasralla, et al.
Clinical Lung Cancer|May 10, 2016
Treatment Patterns for Advanced Non-Small-cell Lung Cancer After Platinum-containing Therapy in U.S. Community Oncology Clinical PracticeCaroline McKay, Thomas Burke, Xiting Cao, et al.
Frontiers in Oncology|November 3, 2022
Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practicesStephen V Liu, Xiaohan Hu, Yeran Li, et al.
Lung Cancer (Amsterdam, Netherlands)|June 29, 2020
In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater"Min Huang, Ralph P Insinga, Thomas Burke, et al.
Pageof 11

Showing results (21-30 of 110) with videos related to

Sort By:
Pageof 11
Frontiers in Oncology|April 11, 2022
Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1Vamsidhar Velcheti, Xiaohan Hu, Lingfeng Yang, et al.
JAAD Case Reports|September 22, 2017
Remission of hidradenitis suppurativa after bariatric surgeryCatriona Gallagher, Shivashini Kirthi, Thomas Burke, et al.
Immunotherapy|June 12, 2019
First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatmentVamsidhar Velcheti, Sheenu Chandwani, Xin Chen, et al.
Clinical Therapeutics|October 9, 2007
Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational studyEric Van Ganse, Laurent Laforest, Thomas Burke, et al.
Lung Cancer (Amsterdam, Netherlands)|April 11, 2021
Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparisonBalazs Halmos, Thomas Burke, Chrysostomos Kalyvas, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|November 29, 2005
Does the crack silently break the back? Long-term follow-up and assessment of risk factors for regional osteoporosis following tibial shaft fracturesMohamed Khalid, Gregory Heffernan, Ann Brannigan, et al.
Frontline Gastroenterology|December 31, 2021
Recent advances in liver transplantationN Thomas Burke, James B Maurice, David Nasralla, et al.
Clinical Lung Cancer|May 10, 2016
Treatment Patterns for Advanced Non-Small-cell Lung Cancer After Platinum-containing Therapy in U.S. Community Oncology Clinical PracticeCaroline McKay, Thomas Burke, Xiting Cao, et al.
Frontiers in Oncology|November 3, 2022
Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practicesStephen V Liu, Xiaohan Hu, Yeran Li, et al.
Lung Cancer (Amsterdam, Netherlands)|June 29, 2020
In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater"Min Huang, Ralph P Insinga, Thomas Burke, et al.
Pageof 11